We serve Chemical Name:7-fluoro-6-methyl-3,4-dihydro-2H-naphthalen-1-one CAS:182182-24-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:7-fluoro-6-methyl-3,4-dihydro-2H-naphthalen-1-one
CAS.NO:182182-24-7
Synonyms:7-fluoro-6-methyl-1-tetralone
Molecular Formula:C11H11FO
Molecular Weight:178.20300
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:286ºC at 760 mmHg
Density:1.162g/cm3
Index of Refraction:1.538
PSA:17.07000
Exact Mass:178.07900
LogP:2.65310
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 7-fluoro-6-methyl-1-tetralone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-fluoro-6-methyl-1-tetralone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-fluoro-6-methyl-1-tetralone Use and application,7-fluoro-6-methyl-1-tetralone technical grade,usp/ep/jp grade.
Related News: The vaccine significantly reduced — by 58% — the accumulation of neurofilament light chain in the blood. This is an important biomarker of neurodegenerative diseases, Novak said — damaged nerve cells release the substance, which leaks into the blood. 7-fluoro-6-methyl-3,4-dihydro-2H-naphthalen-1-one manufacturer The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 7-fluoro-6-methyl-3,4-dihydro-2H-naphthalen-1-one supplier The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 7-fluoro-6-methyl-3,4-dihydro-2H-naphthalen-1-one vendor The vaccine significantly reduced — by 58% — the accumulation of neurofilament light chain in the blood. This is an important biomarker of neurodegenerative diseases, Novak said — damaged nerve cells release the substance, which leaks into the blood. 7-fluoro-6-methyl-3,4-dihydro-2H-naphthalen-1-one factory Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.
